Antibiotic Therapy

Introduction to Antibiotic Therapy

Antibiotic therapy is a crucial aspect of treating various infections, with guidelines provided by reputable societies such as the Infectious Diseases Society of America, the American Thoracic Society, and the American College of Chest Physicians 1, 2, 3

For most bacterial skin and soft tissue infections, treatment with aztreonam for 7-14 days is recommended, as suggested by the Infectious Diseases Society of America 4
Aztreonam can be used as an alternative to β-lactam-based antibiotics for patients with severe penicillin allergy, at a dose of 2 g IV every 8 hours, but coverage for gram-positive organisms should be included, as recommended by the American Thoracic Society and the American College of Chest Physicians 2, 3

Aztreonam is suggested as a preferential choice, in combination with ceftazidime-avibactam, for metallo-β-lactamases-producing CRE infections, due to its good in-vitro synergy against NDM-producing and KPC-producing CRE isolates, and association with lower 30-day mortality and clinical treatment failure rates, as recommended by the Infectious Diseases Society of America, with high strength of evidence 1, 2
The combination of aztreonam with ceftazidime-avibactam shows significant synergy against NDM-producing and KPC-producing CRE isolates, and is associated with lower 30-day mortality and lower clinical treatment failure rates compared to other antimicrobial therapies for MBL-producing CRE infections, with a strength of evidence of high quality, as recommended by the American College of Clinical Microbiology 1
Aztreonam should be used in combination with ceftazidime-avibactam for the treatment of MBL-producing CRE infections, rather than as monotherapy, due to its limited spectrum of activity against other broad-spectrum beta-lactamases or carbapenemases, as recommended by the Infectious Diseases Society of America and the American College of Clinical Microbiology 1, 3

The recommended dose of aztreonam is 1-2 grams IV every 8-12 hours, with a duration of 7-14 days, as stated by the American College of Clinical Microbiology 3
Aztreonam has a unique spectrum of activity, being highly effective against most Enterobacteriaceae, Pseudomonas aeruginosa, Haemophilus influenzae, and Serratia marcescens, but has no activity against gram-positive bacteria and anaerobic bacteria, making it a primary treatment option for infections caused by aerobic gram-negative bacteria, particularly in patients with beta-lactam allergies, as stated by the American College of Physicians 3

Aztreonam is effective for treating urinary tract infections caused by susceptible gram-negative bacteria, particularly in complicated UTIs where other antibiotics may not be suitable due to resistance patterns or allergies, with a good safety profile and minimal side effects, as stated by the American College of Physicians 3